- Raised $5M funding round, Feb 2021
- Raised $14M funding round, Jan 2021
- Raised $5M funding round, Sep 2018
About
Bonus BioGroup is a product-focused biotechnology company applying proprietary technology to supply tissue-regenerating, viable bone grafts. The company develops cell therapy and tissue-engineering products based on autologous bone implants that enable efficient bone transplantation and provide cell-based bone replacement for repairing bone lesions. Bonus BioGroup is the developer of BonoFill, a method for growing high-density 3D bone grafts based on multicell 3D cultures. BonoFill is derived from the patients own cells and constructed from a variety of cells grown in multiple layers within a bioreactor system. BonoFills technology enables the construction of bone grafts outside of the human body (ex vivo) and promotes graft acceptance by the patients body following transplantation. It also allows growth of a human tissue graft tailored to the biological, physical, and clinical needs of each patient, without incurring immune reactions or graft rejection.
Funding history · 4 rounds · $25.6M total
Q&A
- What is Bonus BioGroup's primary focus?
- Bonus BioGroup is a biotechnology company focused on supplying tissue-regenerating, viable bone grafts using proprietary technology. They develop cell therapy and tissue-engineering products based on autologous bone implants.
- What is BonoFill technology?
- BonoFill is a proprietary method developed by Bonus BioGroup for growing high-density 3D bone grafts. It is based on multicell 3D cultures derived from a patient's own cells, grown in multiple layers within a bioreactor system.
- When was Bonus BioGroup founded?
- Bonus BioGroup was founded in October 1981.
- What is Bonus BioGroup's employee count?
- Bonus BioGroup has an employee count in the 11-50 range.
- What is the total amount of funding Bonus BioGroup has raised?
- Bonus BioGroup has raised a total of $25.6 million USD.
- When was Bonus BioGroup's most recent funding round and who participated?
- Bonus BioGroup's most recent funding round was in February 2021, raising $5 million USD with participation from SIBF VC.
- What is Bonus BioGroup's current market capitalization?
- Bonus BioGroup's market capitalization is $96,383,890 USD.
- What is the status of Bonus BioGroup's products?
- Bonus BioGroup's products are currently in the clinical trial stage.
- Who is the CEO and President of Bonus BioGroup?
- Shai Meretzki is the Founder, CEO & President of Bonus BioGroup.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | bonus-bio.com |
|---|---|
| linkedin.com/company/14822062 | |
| facebook.com/BonusBio | |
| YouTube | youtube.com/channel/UChXNkBN4lQ0QKLW1w1Dls_Q |
Identifiers & details
| Founded | 1981-10 |
|---|---|
| Employees (exact) | 41 |
| Market cap | $96.4M |
| Status reason | Public on TASE on Feb, 2012 |
Radar intelligence
Patents
| EPO | 1 |
|---|
Publications (Crossref)
| Works | 1 |
|---|
Web history (Wayback)
| Domain | bonus-bio.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|